Live
- BJP urges EC to stop Cong’s ‘Guarantee Cards’ campaign aimed to 'induce voters'
- Congress cheated Madigas: Dr. RS Praveen Kumar
- CBDT signs record 125 pacts to ease tax payments by big multinational firms
- Kamal Nath accuses BJP of ‘threatening’ Congress leaders in Chhindwara
- Odisha: BJP, BJD allege violation of MCC
- PM Modi lands in Guwahati to kickstart poll campaign
- ‘100 day action plan’ is PM Modi’s signature style for setting goals and meeting targets
- BJP will change the Constitution if they come to power again, says Priyanka Gandhi
- BJP-led NDA to cross 390-mark in Lok Sabha polls, predicts India TV-CNX survey
- Haier launches new TV series in four sizes in India
Dr Reddy’s strengthens OTC portfolio in India
Dr Reddy’s Laboratories Limited further strengthened its presence in over-the-counter (OTC) space in India by launching Nise D spray on Monday. The spray offers quick and targeted pain relief.
Hyderabad: Dr Reddy’s Laboratories Limited further strengthened its presence in over-the-counter (OTC) space in India by launching Nise D spray on Monday. The spray offers quick and targeted pain relief.
Through this new product, the pharma major has expanded its offerings in the therapeutic area of pain relief to consumers. The formulation for Nise D spray comprises three key ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation. “Nise D spray marks our entry into the new segment and further boosts our OTC portfolio.
Nise gel has made a remarkable headway into the market and, looking at the market dynamics and consumer requirements, we expect Nise D spray to have a great momentum and significant market share across regions,” said M V Ramana, EVP & Head, Branded Markets (India & Emerging Countries), Dr Reddy’s said. In India, the market for pain relief products is around Rs 1,700 crore, the company said, citing A C Nielsen Retail Measurement Study MAT August 2015.
